BioSpace News Archive

Located in Kalamazoo, the New GMP-compliant Kilolab and QC Laboratory will manage supply for clinical Phase 1 and early Phase 2

Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”) CEO Philippe Deschamps has been invited to brief the US Congress on the latest technologies, innovations and policies in clinical neuroscience at the 9th Annual Brain Mapping Foundation Congressional briefing at the US Congress on February 25th.

With momentum building for the use of psychedelic substances in the treatment of mental illness, addiction and trauma, Vancouver-based Numinus Wellness Inc. (“Numinus”) is now one of the first in-market, fully integrated companies in the psychedelic space in North America.

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the Cowen 40th Annual Health Care Conference.

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 15/536,237, titled, “Phosphoramidates for the Treatment of Hepatitis B Virus,”

Offers Convenient Access to Key Health Care Services for 12,000 Building Employees

SUMMIT, N.J. , Feb. 24, 2020 /PRNewswire/ -- Quadrivalent formulation of the first-and-only adjuvanted seasonal influenza vaccine for older adults (65+ years) receives FDA approval 1 Designed with MF59® adjuvant to help strengthen, broaden and lengthen the body’s immune response against the influenza strains contained in the vaccine 1,2,3,4 Seqirus announced to

Feb. 24, 2020 13:30 UTC – Updated data from the Phase 1 study in healthy subjects show that MGTA-145, in combination with plerixafor, met all primary and secondary endpoints – – Median of 4.1 million CD34+ cells/kg collected in a single day from eight subjects – – Magenta plans to initiate multiple Phase 2 studies in 2020, in both allogeneic and autologous transplant settings – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Magenta Therapeutics (NASDAQ: MGTA), a clinical

LogiTag Medical Solutions announced the launch of its patent-protected Snap & Go image recognition technology that captures, records and bills medical implants and consumables used during surgery.

Trinity Life Sciences, a global life sciences commercialization solutions provider with extensive experience in launch planning, is sharing lessons learned in its latest report, “Achieving Launch Excellence in this New Decade: Four Must-Haves for an Agile Launch Strategy.”